Inside Health New treatment for menopausal hot flush
Apr 7, 2026
Professor Brantley Hall, a Maryland researcher who built a wearable sensor for measuring flatulence, Dr Manjula Meda, a microbiologist who led a sink‑removal project to curb hospital superbugs, and Dr Margaret McCartney, a GP who interprets clinical trial evidence. They discuss a new non‑hormonal treatment for menopausal hot flushes. They also cover hospital sink redesigns to reduce resistant infections and scientific measurement of flatulence.
AI Snips
Chapters
Transcript
Episode notes
Menovest Simulation Shows Hot Flush Distraction
- James Gallagher wore a Menovest that simulates menopausal hot flushes and felt sudden neck and upper-torso heat, distraction, and anxiety about when the next flush would come.
- Lesley Salem explained the vest is used for about an hour as an empathy tool to show unpredictability and cognitive impact of hot flushes in work/public settings.
New Nonhormonal Drug Reduces Hot Flush Frequency
- Fezolinotant (Vioza) is a new non-hormonal drug approved by NICE for menopausal hot flushes, acting in the brain to modulate temperature regulation.
- Trials showed events fell from ~10/day to 2.6 by week 25 on drug versus 4.6 on placebo, so it helps but doesn't eliminate flushes.
Use Fezolinetant Only For Hot Flushes And With Caution
- Do not expect fezolinetant to treat all menopausal symptoms; it targets hot flushes only and will not relieve vulvovaginal dryness.
- Providers should avoid prescribing it to people with liver disease, current breast or oestrogen-dependent cancers due to safety signals and required liver monitoring.